CD19-targeted CAR T-cell therapy shows a 65% response rate in Richter transformation, with median progression-free survival of 8 months and overall survival of 14.4 months. Early response and age are ...
A first clinical study suggests allogeneic CD19-targeted CAR-T cell therapy can safely induce durable remission in patients with severe, treatment-refractory systemic lupus erythematosus.
UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes ...
An engineered viral protein enhanced the anticancer function of T cells in mice, suggesting a new strategy to improve immunotherapy. Courtney and his team sought to exploit this property of TIP to ...
BI-1808 and pembrolizumab combination shows a 24% ORR in recurrent ovarian cancer, surpassing pembrolizumab monotherapy's 8% ...
Please provide your email address to receive an email when new articles are posted on . ORLANDO — An in vivo chimeric antigen receptor T-cell therapy administered without lymphodepletion exhibited ...
The ability of immune cells-particularly CD8 + T cells-to launch a rapid burst of proliferation inside tumors is key to the success of modern day cancer immunotherapies. However, the factors and ...
A team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and Luigi Naldini, has unveiled a powerful strategy to rejuvenate the ...
T cells represent a central component of the adaptive immune system, orchestrating responses that protect against pathogens while maintaining tolerance towards self-antigens. Their dysregulation, ...
Our immune system functions like well-equipped soldiers or guards to combat pathogens and for the most part, it does a great job! However, some viruses like herpesviruses have a cunning trick up their ...
CAR T-cell therapy was first developed as a lymphoma treatment but has recently been applied to autoimmune diseases, primarily lupus, systemic sclerosis, and myositis. Up to this point, ulcerative ...